Germany · Delayed Price · Currency is EUR Acrux Company Description
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream.
It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores.
The company was incorporated in 1998 and is based in West Melbourne, Australia.
| Country | Australia |
| Founded | 1998 |
| Industry | Pharmaceutical Preparations |
| Employees | 43 |
| CEO | John Warmbrunn |
Contact Details
Address: 103-113, Stanley Street West Melbourne, Victoria 3003 Australia | |
| Phone | 61 3 8379 0100 |
| Website | acrux.com.au |
Stock Details
| Ticker Symbol | FJY |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Warmbrunn | Chief Executive Officer |
| Joanna Johnson | Chief Financial Officer |